THERAPY DOSSIER · th-9a25b59a9197

Human bone marrow mesenchymal stromal cells combined with renal pulsed focused ultrasound pretreatment

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30216653 ↗2018Reported benefit

Mesenchymal stromal cell potency to treat acute kidney injury increased by ultrasound-activated interferon-gamma/interleukin-10 axis.

MouseChemical/toxinC3H wild-type and B6.129S7 interferon-gamma knockoutFemalen = n=6 mice per group across all experimental groupsIntravenous tail vein infusion of MSC; transcutaneous image-guided pulsed focused ultrasound to the kidneysMSC infused in 100 microl per mouse (exact cell number not…pFUS delivered 24 h after cisplatin and MSC infused approximately 4 h after pFUS

Model: Cisplatin-induced acute kidney injury by a single intraperitoneal injection of cisplatin 15 mg/kg on day 0, with food and water withheld for 12 h beforehand

Interferon-gamma preconditioning increased MSC IL-10 in vitro and produced small but significant improvements in BUN and serum creatinine, fewer TUNEL-positive cells and a trend to lower KIM-1 versus unstimulated MSC, without changing MSC homing. In interferon-gamma knockout mice, pFUS nearly doubl…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…